| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 21066 |
| Drug | Osimertinib |
| Brand | Tagrisso® |
| Indication | For adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA Non-Small Cell Lung Cancer whose tumour has epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations. |
| Assessment Process | |
| Rapid review commissioned | 20/12/2021 |
| Rapid review completed | 13/01/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of osimertinib compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 31/01/2022 |
| Pre-submission consultation with Applicant | 15/03/2022 |
| Full submission received from Applicant | 16/08/2022 |
| Preliminary review sent to Applicant | 27/01/2023 |
| NCPE assessment re-commenced | 13/03/2023 |
| Factual accuracy sent to Applicant | 03/05/2023 |
| NCPE assessment re-commenced | 10/05/2023 |
| NCPE assessment completed | 23/05/2023 |
| NCPE assessment outcome | The NCPE recommends that osimertinib not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations March 2024.
